IBAB Ion Beam Applications SA
Ion Beam Applications SA designs, produces, and markets solutions for cancer diagnosis and treatments, serious illnesses, and industrial applications in Belgium, the United States, China, Germany, and India. It operates through four segments, Clinical Proton Therapy; Clinical Dosimetry; IBA Technologies; and IBA Corporate. The company develops ConformalFLASH, a novel technique using the proton Bragg peak; DynamicARC, a technique that allows dynamic spot scanning irradiation and energy switching while the gantry is rotating; Proteus ONE, a compact proton therapy system transforming cancer treatment; Proteus PLUS, a proton therapy solution for cancer centers; and dosimetry solutions that includes radiation therapy; medical imaging; and QUASAR that offers a portfolio of sophisticated phantoms supporting MR guided radiation therapy, motion management, surface guided radiation therapy, geometric distortion analysis, and machine targeting solutions. It also offers radio pharma solutions, including radioisotopes, cyclotrons, and radiochemistry, as well as other integrated and industrial solutions, and services. In addition, the company is involved in construction of proton therapy, and other accelerators equipment and installation services; and operation and maintenance services, as well as sales a license for intellectual property. The company has strategic research and development partnership with SCK CEN, a Belgian nuclear research center focusing on the development of Actinium-225, a radioactive isotope for the treatment of cancer. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.…
Industry Peers
Medical DevicesKey Statistics
About Ion Beam Applications (EBR: IBAB)
›
Ion Beam Applications (EBR: IBAB) is listed on Euronext Brussels, where its shares trade in EUR. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 2,264 employees.
The shares were at 16.40 EUR on 20 November 2026, up 64.2% over 52 weeks. Its 52-week range is 9.990 EUR to 17.76 EUR: the price is 7.7% below the high and 64.2% above the low.
At a market capitalisation of 473.94M EUR, it trades at 19.9 times trailing earnings and 14.8 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.5, a discount of 22% for IBAB. It pays a dividend yielding 1.51% (it pays out 31% of its earnings), against a median of 2.35% among the dividend payers in that peer group.
Ion Beam Applications reports return on equity of 10.0%, an operating margin of 6.4% and revenue up 6.2% year over year.
Its debt exceeds its cash by 74.97M EUR, a debt-to-equity ratio of 0.92. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 4 analysts cover the stock; their mean price target of 17.63 EUR is 7.5% above the current price. The next earnings report is expected on 18 March 2027.